← Back to Search

Behavioural Intervention

Geriatric Care Optimization for Blood Cancers

N/A

Waitlist Available

Led By Sarah Wall, MD

Research Sponsored by Ohio State University Comprehensive Cancer Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Diagnosed with hematologic malignancy or bone marrow failure syndrome eligible for allogeneic hematopoietic cell transplantation. This includes acute myeloid leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myelofibrosis, chronic myeloid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma, and aplastic anemia. Disease specific eligibility for allo-HCT to be determined by treating physician

Age >= 60 years

Timeline

Screening 3 weeks

Treatment Varies

Follow Up at 6 months before transplant, up to 12 months after transplant

Awards & highlights

Study Summary

This trial studies if a plan tailored to the individual can improve survival & quality of life for patients over 60 w/ hematologic malignancy or bone marrow failure syndrome receiving an allogeneic hematopoietic cell transplant.

Who is the study for?

This trial is for people over 60 with blood cancers or bone marrow failure who are eligible for a stem cell transplant. They must be able to understand English and commit to the study's full duration. Those with dementia, no transplant planned within 6 months, or a scheduled transplant within 30 days can't join.Check my eligibility

What is being tested?

The OTIS Study tests a geriatric optimization plan (GO!) aimed at improving survival in older adults through personalized lifestyle changes like diet, sleep, activity adjustments, medication reviews, and specialist referrals before their stem cell transplants.See study design

What are the potential side effects?

Since this trial focuses on health promotion rather than drugs or invasive procedures, side effects may include discomfort from lifestyle changes or stress from additional medical appointments and assessments.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am eligible for a stem cell transplant due to my blood-related cancer or condition.

Select...

I am 60 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ at 6 months before transplant, up to 12 months after transplant

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~at 6 months before transplant, up to 12 months after transplant

This trial's timeline: 3 weeks for screening, Varies for treatment, and at 6 months before transplant, up to 12 months after transplant for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in 6-Minute Walk Test distance

Secondary outcome measures

Adherence to prescribed geriatric optimization plan (GO!) prescription

Change in Short Physical Performance Battery score

Change in cognitive and mental health

+6 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Supportive care (GO!)Experimental Treatment4 Interventions

Patients undergo personalized GO! plan consisting of study visits over 50 minutes at baseline and 6 months after first visit or at the time of hospital admission for bone marrow transplant and over 25 minutes at 3 and 12 months after transplant. Patients complete questionnaires once a month for up to 6 months and wear an accelerometer for up to 6 months.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

Ohio State University Comprehensive Cancer CenterLead Sponsor

320 Previous Clinical Trials

290,137 Total Patients Enrolled

11 Trials studying Multiple Myeloma

5,410 Patients Enrolled for Multiple Myeloma

Sarah Wall, MDPrincipal InvestigatorOhio State University Comprehensive Cancer Center

Media Library

Geriatric Optimization Plan (Behavioural Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05972577 — N/A

Multiple Myeloma Research Study Groups: Supportive care (GO!)

Multiple Myeloma Clinical Trial 2023: Geriatric Optimization Plan Highlights & Side Effects. Trial Name: NCT05972577 — N/A

Geriatric Optimization Plan (Behavioural Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05972577 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there still spots available for patient participation in this trial?

"Clinicaltrials.gov indicates that this study is currently not enrolling new participants, as the trial was most recently updated on July 24th 2023. Nonetheless, 6153 other medical experiments are actively seeking out patients to take part in their research endeavours."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study

Sarah Wall 2021. "Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05972577.

All > Aplastic Anemia > Myelofibrosis